Brokerages Set Alpha Cognition Inc. (NASDAQ:ACOG) Price Target at $18.00

Shares of Alpha Cognition Inc. (NASDAQ:ACOGGet Free Report) have been given an average recommendation of “Buy” by the five analysts that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.00.

A number of analysts have commented on the stock. Maxim Group assumed coverage on shares of Alpha Cognition in a report on Friday, May 29th. They set a “buy” rating and a $12.00 target price for the company. B. Riley Financial began coverage on shares of Alpha Cognition in a research report on Thursday, August 20th. They set a “buy” rating and a $21.00 price objective for the company. Craig Hallum reaffirmed a “buy” rating and issued a $17.00 target price on shares of Alpha Cognition in a report on Friday, August 14th. Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright raised their price objective on Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, August 17th.

Get Our Latest Stock Analysis on ACOG

Insider Buying and Selling

In other news, Director Robert Wills bought 10,000 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were bought at an average price of $9.62 per share, for a total transaction of $96,200.00. Following the purchase, the director owned 32,241 shares in the company, valued at approximately $310,158.42. The trade was a 44.96% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Opaleye Management Inc. boosted its holdings in Alpha Cognition by 13.0% in the 2nd quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock worth $20,905,000 after buying an additional 333,517 shares during the period. AWM Investment Company Inc. purchased a new position in shares of Alpha Cognition in the second quarter valued at about $12,073,000. Aristides Capital LLC boosted its stake in shares of Alpha Cognition by 1.4% in the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock worth $1,200,000 after acquiring an additional 3,052 shares during the period. Finally, ACT Capital Management LLC purchased a new stake in shares of Alpha Cognition during the fourth quarter worth about $335,000.

Alpha Cognition Trading Down 0.2%

Shares of ACOG stock opened at $8.83 on Friday. Alpha Cognition has a 12-month low of $4.50 and a 12-month high of $10.14. The stock has a market capitalization of $192.32 million, a P/E ratio of -8.03 and a beta of 2.32. The firm’s 50 day moving average is $8.84 and its 200 day moving average is $7.18.

Alpha Cognition (NASDAQ:ACOGGet Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The firm had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. As a group, equities analysts predict that Alpha Cognition will post -1.38 earnings per share for the current year.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition, Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative disorders. The company’s work centers on therapies intended to address unmet needs in conditions affecting cognition and the central nervous system, including Alzheimer’s disease.

Its lead product, ZUNOVO (donepezil hydrochloride), is an orally disintegrating tablet formulation of donepezil for the treatment of mild to moderate Alzheimer’s disease. The formulation is designed to dissolve in the mouth and may provide an alternative for patients who have difficulty swallowing conventional tablets.

Featured Stories

Analyst Recommendations for Alpha Cognition (NASDAQ:ACOG)

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.